Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-626 in Healthy Adult Subjects
NCT06674525Phase 1Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 626 (6 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Number of participants with Adverse Events at 90 days. Started Dec 2024; status: completed.
02
Drugs
626
Beyond the preview
Go deeper on NCT06674525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674525.